55 related articles for article (PubMed ID: 1292628)
1. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
Liu J; Finke J; Krauss JC; Shu S; Plautz GE
Cancer Immunol Immunother; 1998 Jul; 46(5):268-76. PubMed ID: 9690455
[TBL] [Abstract][Full Text] [Related]
2. Expression of the p56(Lck) Y505F mutation in CD45-deficient mice rescues thymocyte development.
Seavitt JR; White LS; Murphy KM; Loh DY; Perlmutter RM; Thomas ML
Mol Cell Biol; 1999 Jun; 19(6):4200-8. PubMed ID: 10330160
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic signals in the unique domain target p56(lck) to the plasma membrane independently of CD4.
Bijlmakers MJ; Isobe-Nakamura M; Ruddock LJ; Marsh M
J Cell Biol; 1997 Jun; 137(5):1029-40. PubMed ID: 9166404
[TBL] [Abstract][Full Text] [Related]
4. PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor.
Fujimura A; Nakayama K; Imaizumi A; Kawamoto M; Oyama Y; Ichimiya S; Umebayashi M; Koya N; Morisaki T; Nakagawa T; Onishi H
Cancer Immunol Immunother; 2019 Oct; 68(10):1649-1660. PubMed ID: 31562536
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting LCK in acute lymphoblastic leukemia.
Chen Y; Zhang K; Tan J; Fan Z; Fu Y; Li X; Liu B; Wang G
Bioorg Chem; 2024 Mar; 144():107180. PubMed ID: 38335758
[TBL] [Abstract][Full Text] [Related]
6. The effector functions of mature T lymphocytes are impaired in transgenic mice expressing the SH2 domain of TSAd/Lad.
Choi Y; Park E; Ahn E; Park I; Yun Y
Mol Cells; 2009 Sep; 28(3):183-8. PubMed ID: 19756394
[TBL] [Abstract][Full Text] [Related]
7. Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients.
Choi SH; Chung EJ; Whang DY; Lee SS; Jang YS; Kim CW
Cancer Immunol Immunother; 1998 Feb; 45(6):299-305. PubMed ID: 9490199
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
9. Identification of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffolds as potent Lck inhibitors as anti-cancer agents.
Ji SH; Kim HB; Song Y; Chung HW; Lee DH; Jung C; Ko Y; Han SJ
Bioorg Med Chem Lett; 2024 Apr; 102():129645. PubMed ID: 38316368
[TBL] [Abstract][Full Text] [Related]
10. A partial human LCK defect causes a T cell immunodeficiency with intestinal inflammation.
Lui VG; Hoenig M; Cabrera-Martinez B; Baxter RM; Garcia-Perez JE; Bailey O; Acharya A; Lundquist K; Capera J; Matusewicz P; Hartl FA; D'Abramo M; Alba J; Jacobsen EM; Niewolik D; Lorenz M; Pannicke U; Schulz AS; Debatin KM; Schamel WW; Minguet S; Gumbart JC; Dustin ML; Cambier JC; Schwarz K; Hsieh EWY
J Exp Med; 2024 Jan; 221(1):. PubMed ID: 37962568
[TBL] [Abstract][Full Text] [Related]
11. Direct observation and quantitative analysis of Lck exchange between plasma membrane and cytosol in living T cells.
Zimmermann L; Paster W; Weghuber J; Eckerstorfer P; Stockinger H; Schütz GJ
J Biol Chem; 2010 Feb; 285(9):6063-70. PubMed ID: 20040600
[TBL] [Abstract][Full Text] [Related]
12. An immunosuppressive antibody-drug conjugate.
Wang RE; Liu T; Wang Y; Cao Y; Du J; Luo X; Deshmukh V; Kim CH; Lawson BR; Tremblay MS; Young TS; Kazane SA; Wang F; Schultz PG
J Am Chem Soc; 2015 Mar; 137(9):3229-32. PubMed ID: 25699419
[TBL] [Abstract][Full Text] [Related]
13. QSAR study of p56(lck) protein tyrosine kinase inhibitory activity of flavonoid derivatives using MLR and GA-PLS.
Fassihi A; Sabet R
Int J Mol Sci; 2008 Sep; 9(9):1876-1892. PubMed ID: 19325836
[TBL] [Abstract][Full Text] [Related]
14. LCK-SafeScreen-Model: An Advanced Ensemble Machine Learning Approach for Estimating the Binding Affinity between Compounds and LCK Target.
Cheng Y; Ji C; Xu J; Chen R; Guo Y; Bian Q; Shen Z; Zhang B
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959801
[TBL] [Abstract][Full Text] [Related]
15. All-photonic kinase inhibitors: light-controlled release-and-report inhibition.
Fleming CL; Benitez-Martin C; Bernson E; Xu Y; Kristenson L; Inghardt T; Lundbäck T; Thorén FB; Grøtli M; Andréasson J
Chem Sci; 2024 May; 15(18):6897-6905. PubMed ID: 38725520
[TBL] [Abstract][Full Text] [Related]
16. The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim.
Desbien AL; Kappler JW; Marrack P
Proc Natl Acad Sci U S A; 2009 Apr; 106(14):5663-8. PubMed ID: 19293378
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine kinase p56-Lck regulates lymphocyte function-associated 1 adhesion molecule expression, granule exocytosis, and cytolytic effector function in a cloned T cell.
Torigoe T; Millan JA; Chan KW; Taichman R; Brian AA; Reed JC; Tachman R [corrected to Taichman R]
J Exp Med; 1994 Sep; 180(3):1115-27. PubMed ID: 7914906
[TBL] [Abstract][Full Text] [Related]
18. Gene transfer investigations of p56-LCK function in IL-2-dependent T-cell lines: implications for mechanisms of IL-2-signal transduction.
Taichman RS; Torigoe T; Tanaka S; Miyashita T; Reed JC
Cytokine; 1992 Nov; 4(6):441-53. PubMed ID: 1292628
[TBL] [Abstract][Full Text] [Related]
19. Evidence that protein tyrosine kinase p56-Lck regulates the activity of phosphatidylinositol-3'-kinase in interleukin-2-dependent T-cells.
Taichman R; Merida I; Torigoe T; Gaulton GN; Reed JC
J Biol Chem; 1993 Sep; 268(27):20031-6. PubMed ID: 8397196
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
